



21 May 2020

ASX Market Announcements
Australian Securities Exchange
Level 5, 20 Bridge Street
SYDNEY NSW 2000

By Electronic Lodgement

Dear Sir/Madam

Results of May 2020 General Meeting

The Board of Cellmid Limited (ASX:CDY) (**Company**) is pleased to advise that shareholders of the Company **passed all Resolutions** in the Notice of Meeting dated 21 April 2020 at the General Meeting held today at 2:00pm (Sydney time) by way of poll.

In accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act a summary of the proxy votes and the number of votes cast on each resolution in the poll is attached:

Yours faithfully

Lee Tamplin

Company Secretary

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au. Cellmid's wholly owned subsidiary, Lyramid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Most recently, the Company commenced sale of a point of care antibody test for SARS-CoV-2.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.

CELLMID LIMITED ACN 111 304 119 ASX I CDY

Suite 204, Level 2, 55 Clarence Street,
Sydney NSW 2000 AUSTRALIA

TELEPHONE +61 2 9221 6830 FACSIMILE +61 2 9221 8535

WEB www.cellmid.com.au

Disclosure of Proxy Votes

Cellmid Limited

General Meeting

Thursday, 21 May 2020



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Approval of Issue of Shares to Maria Halasz, Director of the Company	P	19,845,750	17,446,450 87.91%	2,246,095 11.32%	91,866	153,205 0.77%	17,599,655 88.68%	2,246,095 11.32%	91,866
2 Approval of Issue of Shares to Dennis Eck, Director of the Company	P	14,286,718	12,500,330 87.50%	1,703,183 11.92%	91,866	83,205 0.58%	12,583,535 88.08%	1,703,183 11.92%	91,866
3 Approval of Issue of Broker Options	P	22,412,177	19,269,700 85.98%	2,986,770 13.33%	145,377	155,707 0.69%	19,425,407 86.67%	2,986,770 13.33%	145,377
4 Ratification of Issue of Placement Shares	P	18,781,316	17,070,416 90.89%	1,569,284 8.36%	141,478	141,616 0.75%	17,212,032 91.64%	1,569,284 8.36%	141,478

